Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Estradiol and raloxifene decrease the formation of multinucleate cells in human bone marrow cultures.

Ana Claudia Ramalho1, Philippe Couttet, Claude Baudoin

  • 1INSERM U. 349, Lariboisière Hospital, 2, rue Ambroise-Paré, 75475 Paris Cedex 10 France.

European Cytokine Network
|April 17, 2002
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transcriptional changes in non-human primate tissues after intrathecal delivery of serotype 9 adeno-associated viral vector: Insights into organ toxicities.

Molecular therapy. Methods & clinical development·2025
Same author

Liver enzyme delayed clearance in rat treated by CSF1 receptor specific antagonist Sotuletinib.

Current research in toxicology·2022
Same author

Identification of marker genes to monitor residual iPSCs in iPSC-derived products.

Cytotherapy·2022
Same author

Methodological considerations for measuring biofluid-based microRNA biomarkers.

Critical reviews in toxicology·2021
Same author

Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4.

Journal of medicinal chemistry·2020
Same author

Time in range: a new parameter to evaluate blood glucose control in patients with diabetes.

Diabetology & metabolic syndrome·2020

Estrogen (E2) deficiency increases bone turnover postmenopause. Both estradiol and Raloxifene inhibit osteoclast differentiation in human bone marrow cells, likely mediated by estrogen receptor alpha (ER-alpha).

Area of Science:

  • Endocrinology
  • Bone Biology
  • Cellular and Molecular Medicine

Background:

  • Postmenopausal estrogen deficiency accelerates bone turnover, increasing osteoporosis risk.
  • Estrogen replacement therapy can prevent bone loss, but its cellular mechanisms in bone are not fully elucidated.
  • Human bone marrow cell cultures offer a model to study steroid effects on osteoclastogenesis in vitro.

Purpose of the Study:

  • To investigate the effects of estradiol and Raloxifene on human primary bone marrow cells.
  • To determine the role of estrogen receptors in mediating these effects on osteoclast differentiation.

Main Methods:

  • Human primary bone marrow cells were cultured for 15 days.
  • Effects of 17beta-estradiol and Raloxifene on osteoclast precursors (tartrate-resistant acid phosphatase multinucleate cells) were assessed.

Related Experiment Videos

  • Expression of estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNA was analyzed at different culture time points (5 and 15 days).

    • Main Results:

    • Both 17beta-estradiol and Raloxifene significantly reduced the number of osteoclast precursors.
    • Estrogen receptor alpha (ER-alpha) mRNA was detected early in culture (5 days), but not later (15 days), suggesting involvement in early differentiation events.
    • No significant effect on IL-6 or IL-6-soluble receptor release was observed; osteoclast apoptosis remained unaffected.

    Conclusions:

    • Estradiol and Raloxifene inhibit osteoclast differentiation in human bone marrow mononuclear cell cultures.
    • The observed effects are likely mediated through estrogen receptor alpha (ER-alpha), potentially acting on early stages of osteoclastogenesis.
    • This in vitro model provides insights into the mechanisms by which estrogen and SERMs influence bone remodeling.